Latest Revenue Growth News

Althea Group Holdings reported significant cash outflows in Q2 2025 due to one-off costs but anticipates operational improvements and revenue growth from its North American business units.

Lucapa Diamond Company reports a remarkable 104% increase in diamond carats recovered at its Lulo Alluvial Mine in Q2 2025, alongside a 9% rise in its inferred diamond resource, signaling robust operational momentum despite administration status.

Cardiex Limited reported a $3 million cash outflow in Q4 2025 but is banking on cost reductions and new product sales to improve its financial footing. The company also secured $6.5 million through a capital raise to bolster its runway.

AVADA Group Limited reported a strong quarter with positive operating cash flows and significant debt reduction, while initiating a strategic review of its New Zealand operations amid challenging market conditions.

Nutritional Growth Solutions reports a 13.6% revenue dip in Q2 FY25 but completes major CVS rollout and expands Walmart product range, improving cash flow and inventory.

Atomos Limited faced a challenging Q4 FY25 with US tariff disruptions but rebounded strongly in June, launching new products and appointing Peter Barber as CEO to drive future growth.

Oakridge International reported robust revenue growth and expanded its partner network in Q4 2025, underpinning a promising outlook in healthcare technology. The company also advanced product innovation aligned with new industry standards.

Gathid Ltd reported a robust 14% quarterly increase in Annual Recurring Revenue to $1.936 million, driven by new customer wins and expansions, even as a legal dispute over its physical security business sale remains unresolved.

Investor Centre Limited is progressing a key capital raising while its subsidiary Pulse Markets grows wholesale trading operations, signaling strategic momentum despite modest cash outflows.

Argent BioPharma has achieved a significant milestone by commencing formal supply of its EU-GMP cannabinoid API for epilepsy treatment at a leading Slovenian hospital and gaining prescription approval for CannEpil™ in Germany, marking key steps in its European expansion.

Elixinol Wellness reported a 10.8% revenue increase in Q2 2025, supported by improved cash receipts and a focused cost containment program. The company secured new funding and launched a menopause-targeted product, positioning itself for margin growth and profitability in H2.

Weebit Nano reports solid progress in Q4 FY25 with key technology milestones and its first product design license, backed by a strong cash position.